Request Demo

Last update 18 Sep 2025

Biotin

Last update 18 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy.

Drug Type

Small molecule drug

Synonyms

(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid

+ [16]

Target

ABCD1

Action

inhibitors

Mechanism

ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal DiseasesNervous System Diseases+ [2]

Active Indication

Diabetes MellitusEczemaAlzheimer Disease+ [2]

Inactive Indication

Amyotrophic Lateral SclerosisCharcot-Marie-Tooth Disease, Type IaCharcot-Marie-Tooth Disease, Type Ib+ [6]

Originator Organization-

Active Organization

Washington & Jefferson College

Harvard Medical SchoolCiberer

+ [1]

Inactive Organization

MedDay Pharmaceuticals SA

License Organization-

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC10H16N2O3S

InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N

CAS Registry58-85-5

Clinical Trials associated with Biotin

TCTR20250506001

/ CompletedPhase 2/3IIT

Is the addition of Oral Biotin in PRP more beneficial for treating male pattrten hair loss compared to PRp alone?A randamized controlo trial.

Start Date01 Jan 2024

Sponsor / Collaborator-

TCTR20240411004

/ CompletedPhase 2IIT

An Experimental Study on the effect of biotin on Measurement of FT3, FT4 and TSH in healthy adults

Start Date22 Aug 2023

Sponsor / Collaborator-

CTRI/2023/07/055359

/ CompletedNot Applicable

A Randomized Double-Blind Placebo-Controlled Safety and Efficacy Study of Plant Based Biotin and Plant Based Biotin with Silica in Healthy Adult Human Subjects with complaints of Hair Fall Thin Dry & Brittle Hair and Dry Skin - NIL

Start Date01 Aug 2023

Sponsor / Collaborator-

100 Clinical Results associated with Biotin

100 Translational Medicine associated with Biotin

100 Patents (Medical) associated with Biotin

24,233

Literatures (Medical) associated with Biotin

31 Dec 2025·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity

Article

Author: Xu, Xiao-Shuang ; Li, Yimin ; Zhang, Da-Wei ; Xu, Lei ; Xu, Xiaojun ; Xie, Liangxu ; Fu, Zhiguo

The nucleocapsid protein (NP) of SARS-CoV-2, an RNA-binding protein, is capable of undergoing liquid-liquid phase separation (LLPS) during viral infection, which plays a crucial role in virus assembly, replication, and immune regulation. In this study, we developed a homogeneous time-resolved fluorescence (HTRF) method for identifying inhibitors of the SARS-CoV-2 NP-RNA interaction. Using this HTRF-based approach, we identified two natural products, sennoside A and sennoside B, as effective blockers of this interaction. Bio-layer interferometry assays confirmed that both sennosides directly bind to the NP, with binding sites located within the C-terminal domain. Additionally, fluorescence recovery after photobleaching (FRAP) experiments revealed that sennoside B significantly inhibited RNA-induced LLPS of the NP, while sennoside A displayed comparatively weaker activity. Thus, the developed HTRF-based assay is a valuable tool for identifying novel compounds that disrupt the RNA-binding activity and LLPS of the SARS-CoV-2 NP. Our findings may facilitate the development of antiviral drugs targeting SARS-CoV-2 NP.

31 Dec 2025·Journal of the International Society of Sports Nutrition

Survey of nutritional intake status in college baseball players

Article

Author: Aoyama, Yuka ; Tanaka, Mamoru ; Seguchi, Manato ; Iio, Yoko ; Kozai, Hana ; Mori, Yukihiro ; Ito, Morihiro

BACKGROUND:

Diet is closely related to exercise performance. To improve athletes' performance and manage their condition, it is important to get sufficient energy and various nutrients. Thus, it is necessary that athletes understand their nutritional intake status to improve performance and maintain health. This study aimed to explore the nutritional intake status of college baseball players using the Food Frequency Questionnaire (FFQ). Furthermore, the characteristics of their nutritional intake status with respect to athletic performance were evaluated. The result of this studyprovide an opportunity for many under-developed college athletes with irregular lifestyles to recognize and improve their nutritional problems.

METHODS:

In October 2022, a questionnaire survey of 116 male members of a college baseball club was conducted. Of whom, 100 (94.3%) members responded to the survey and 92 (92.0%) provided valid responses. The survey items included basic characteristics such as college grade and type of living arrangement, and information on living conditions, e.g. whether the participant ate breakfast. Nutritional intake was evaluated using the FFQ. Players were divided into the first (regular players in official games), second (bench players in official games), third (players who may join the second or higher team in the future), and fourth teams (players who do not belong to the first to third teams); these categories were used as a marker of performance level. The Kruskal-Wallis test was used to analyze the association between the performance levels of baseball players and the intake of each nutrient and food group obtained by the FFQ. For items that showed a significant association, inter-group comparison was performed using the Dunn-Bonferroni method.

RESULTS:

Carbohydrate intake was greater in the second team compared with the third and fourth teams; saturated and monounsaturated fatty acid intake was higher in the third team compared with the fourth team. Calcium, zinc, copper, manganese, insoluble dietary fiber, iodine, and molybdenum intake was higher in the second team compared with the fourth team. Intake of grains, sugar, dairy, and total energy was significantly higher in the second team compared with the fourth team. However, the protein intake ratio was significantly lower in the second team compared with the fourth team. Overall, energy deficiency and associated deficiencies in protein, fat, and carbohydrate were observed, in addition to dietary fiber and calcium deficiencies. The intake of several food groups appeared inadequate, such as potatoes, beans, vegetables, fruits, eggs, milk, and fats.

CONCLUSIONS:

The study showed deficiencies in the amount of energy and nutrients such as protein, fat, and carbohydrate in college baseball players. Differences in the intake of carbohydrate, calcium, and insoluble dietary fiber among different performance levels were observed, with significantly higher intake of carbohydrate, calcium, and insoluble dietary fiber in the second team. Implementing organized and strategic remedial measures and athletes' identification of nutritional problems are vital to overcome nutritional and energy deficiencies. This study provides useful information for the development of strategies to support nutritional intake in college baseball players.

31 Dec 2025·Plant Signaling & Behavior

Screening and transcriptomic profiling of tobacco growth-promoting arbuscular mycorrhizal fungi

Article

Author: Zhong, Yu ; Luo, Xiao-Qin ; Xia, Ti-Yuan ; Bi, Xiao-Xu ; Deng, Li-Juan ; Zhang, Yu-Ping ; Huang, Bo ; Yin, Min ; Yang, Shuang-Lin ; Ren, Zhen ; Qian, Ying-Ying

Tobacco is a significant economic crop cultivated in various regions of China. Arbuscular mycorrhizal fungi (AMF) can establish a symbiotic relationship with tobacco and regulate its growth. However, the influences of indigenous AMF on the growth and development of tobacco and their symbiotic mechanisms remain unclear. In this study, a pot inoculation experiment was conducted, revealing that six inoculants - Acaulospora bireticulata(Ab), Septoglomus viscosum(Sv), Funneliformis mosseae(Fm), Claroideoglomus etunicatum(Ce), Rhizophagus intraradices(Ri), and the mixed inoculant (H) - all formed stable symbiotic relationships with tobacco. These inoculants were found to enhance the activities of SOD, POD, PPO, and PAL in tobacco leaves, increase chlorophyll content, IAA content， CTK content， soluble sugars, and proline levels while reducing malondialdehyde content. Notably, among these inoculants, Fm exhibited significantly higher mycorrhizal infection density, arbuscular abundance, and soil spore density in the root systems of tobacco plants compared to other treatments. Membership function analysis confirmed that Fm had the most pronounced growth-promoting effect on tobacco. The transcriptome analysis results of different treatments of CK and inoculation with Fm revealed that 3,903 genes were upregulated and 4,196 genes were downregulated in the roots and stems of tobacco. Enrichment analysis indicated that the majority of these genes were annotated in related pathways such as biological processes, molecular functions, and metabolism. Furthermore, differentially expressed genes associated with auxin, cytokinin, antioxidant enzymes, and carotenoids were significantly enriched in their respective pathways, potentially indirectly influencing the regulation of tobacco plant growth. This study provides a theoretical foundation for the development and application of AMF inoculants to enhance tobacco growth.

News (Medical) associated with Biotin

17 Jun 2024

·www.sciencedaily.com

Treating the gut-brain connection with B vitamins to treat Parkinson's Disease

A study has revealed a link between gut microbiota and Parkinson's disease. The researchers discovered a decrease in bacterial genes related to the synthesis of vitamins B2 and B7. The lack of these genes was associated with reduced intestinal short-chain fatty acids and polyamines, agents that maintain the intestinal barrier and prevent the leakage of toxins into the blood that can then access the brain. Using B vitamin therapy to address these deficiencies may restore the barrier and treat Parkinson's disease. A study led by Nagoya University Graduate School of Medicine in Japan has revealed a link between gut microbiota and Parkinson's disease (PD). The researchers found a reduction in the gut bacteria of genes responsible for synthesizing the essential B vitamins B2 and B7. They also identified a relationship between the lack of these genes and low levels of agents that help maintain the integrity of the intestinal barrier. This barrier prevents toxins from entering the bloodstream, which causes the inflammation seen in PD. Their findings, published in npj Parkinson's Disease, suggest that treatment with B vitamins to address these deficiencies can be used to treat PD. PD is characterized by a variety of physical symptoms that hinder daily activities and mobility, such as shaking, slow movement, stiffness, and balance problems. While the frequency of PD may vary between different populations, it is estimated to affect approximately 1-2% of individuals aged 55 years or older. Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota. In ideal conditions, gut microbiota produce SCFAs and polyamines, which maintain the intestinal barrier that prevents toxins entering the bloodstream. Toxins in the blood can be carried to the brain where they cause inflammation and affect neurotransmission processes that are critical for maintaining mental health. To better understand the relationship between the microbial characteristics of the gut in PD, Hiroshi Nishiwaki and Jun Ueyama from the Nagoya University Graduate School of Medicine conducted a metanalysis of stool samples from patients with PD from Japan, the United States, Germany, China, and Taiwan. They used shotgun sequencing, a technique that sequences all genetic material in a sample. This is an invaluable tool because it offers researchers a better understanding of the microbial community and genetic makeup of the sample. They observed a decrease in the bacterial genes responsible for the synthesizing of riboflavin (vitamin B2) and biotin (vitamin B7) in patients diagnosed with PD. Riboflavin and biotin, derived from both food and gut microbiota, have anti-inflammatory properties, which may counteract the neuroinflammation seen in diseases like PD. B vitamins play crucial roles in the metabolic processes that influence the production and functions of short-chain fatty acids (SCFAs) and polyamines, two agents that help maintain the integrity of the intestinal barrier, preventing toxins entering the bloodstream. An examination of fecal metabolites revealed decreases of both in patients with PD. The findings indicate a potential explanation for the progression of PD. "Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in PD," Nishiwaki explained. "This higher permeability exposes nerves to toxins, contributing to abnormal aggregation of alpha-synuclein, activating the immune cells in the brain, and leading to long-term inflammation." He added, "Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue for alleviating PD symptoms and slowing disease progression." The results of the study highlight the importance of understanding the complex relationship among gut microbiota, metabolic pathways, and neurodegeneration. In the coming years, therapy could potentially be customized based on the unique microbiome pro each patient. By altering bacterial levels in the microbiome, doctors can potentially delay the onset of symptoms associated with diseases like PD. "We could perform gut microbiota analysis on patients or conduct fecal metabolite analysis," Nishiwaki said. "Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with decreased levels, potentially creating an effective treatment."

Microbial therapy

12 Mar 2024

·www.prnewswire.com

Bizz Energy Can Help Build Muscle and Boost Metabolism

The Nutrition-Filled Beverage Is Rewriting the Script When It Comes to Energy Drinks FORT LAUDERDALE, Fla., March 12, 2024 /PRNewswire/ -- Traditional energy beverages have a negative reputation for unhealthy ingredients and sugary crashes. Bizz Energy was designed to be the ultimate zero-sugar energy drink. The healthy alternative to the classic concept was developed by a team led by entrepreneur Gavin Jacono. Part of the goal with Bizz Energy is to provide a potent dose of clean, sugar-free, crashless energy. However, Jacono and his team have gone above and beyond to ensure that the nutritional elements of their formula deliver more than a punchy pick-me-up. "Part of the point with Bizz Energy has always been to be a clean energy drink option," explains Jacono. "We want health-conscious individuals to be able to use it as a way to tap energy without compromising their health in the process. But our goal from day one was much bigger than that. We wanted a drink that could enhance performance on a nutritional level. We wanted something that brought together the ideas of an energy drink and a supplement." The first step in achieving this was to avoid classic sweet tooth ingredients, like sugar, high fructose corn syrup, and even aspartame. In addition, the group avoided any harmful chemicals or additives. When it came to the energy part of the process, the R&D team managed to create a unique form of soluble Turkesterone. The natural ecdysteroid has a reputation for stimulating physical and mental energy. This works alongside a punchy per-can dose of 200mg of caffeine anhydrous. Jacono's team also looked for ingredients that could provide a net nutritional positive to the consumer. They included ingredients like creatine and essential amino acids to help with muscle growth and protein synthesis. They also included Niacin and Biotin to support an active metabolism. In the end, the Bizz Energy formula is much more than an average energy drink — or even an improved one. It functions as a dual energy booster and supplement. It can supercharge the mind, energize the body, improve physical performance, and enhance whatever mental or physical activity an individual is attempting to accomplish. Bizz Energy is a refreshing new take on a classic concept. It is a clean, crashless, and nutritious energy drink built to help people reach their goals and go the distance. A bout Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Contact: Gavin Jacono 516-637-8701 374108@email4pr.com SOURCE Bizz Energy

20 Nov 2023

·www.prnewswire.com

Designs for Health Launches Two Collagen Formulas, Whole Beauty Collagen™ & Collagen + MCT

Leading supplement brand now offers three unique researched-back collagen products PALM COAST, Fla., Nov. 20, 2023 /PRNewswire/ -- Designs for Health, the expert-recommended and preferred brand for high-quality, professional strength, research-backed supplements, and recipient of the 2023 Top Supplement Manufacturing Company award ** today announced the launch of Whole Beauty Collagen™ and Collagen + MCT. These products complement the company's bestselling Whole Body Collagen, now offering consumers three superior, efficacious collagen formulas. Whole Beauty Collagen™ is a convenient once-daily powder featuring hydrolyzed collagen peptides and Lustriva®, a patented, clinically researched blend of stabilized biotin and silica, to provide comprehensive support for hair, skin, and nails.* Evidence suggests that Lustriva® may help promote hair fullness, optimal skin texture, and nail strength.* Additionally, the magnesium biotinate used in this formula may have 40 times greater dissolvability and absorption than the biotin used in common beauty products. Collagen + MCT is a keto-friendly powder featuring hydrolyzed collagen peptides from grass-fed, pasture-raised bovine sources and medium-chain triglycerides (C8 & C10 MCTs) from highly refined coconut oil. MCTs metabolize differently than other fats; the body converts them into ketones, even when not on a ketogenic diet, and provide a quick source of energy that most cells and tissues can use. They are especially known for fueling the brain, heart, and skeletal muscles. Research also suggests that MCTs may provide fuel for brain cells, helping to support cognitive function and mental clarity.* Whole Body Collagen is a synergistic formulation designed to benefit the health of bones, joints, and skin.* It contains the research-backed collagen peptide blends Verisol®, Fortigel®, and Fortibone® derived from specific dietary collagen proteins and produced with proprietary hydrolyzation technologies to optimize their beneficial properties. This unique blend is supported by clinical research showing its efficacy for collagen production, bone strength, joint health and integrity, and skin elasticity.* "While the market for collagen supplements has skyrocketed in recent years, all collagen products are not created equal, which is why we are proud to offer three high-quality research-backed formulations that consumers and practitioners can trust," said Chief Medical Officer, Dr. David M. Brady at Designs for Health. "Collagen makes up roughly 30% of the body's protein and 75% of the skin's structure; however, we start to produce less of it as we age, making supplementation vital to helping the body rebuild the collagen that it depends on. Our three unique SKUs have been carefully formulated to provide adults with an easy and convenient way to incorporate specific molecular weight clinically studied collagen into their daily wellness routines at any age." Designs for Health began in 1989 as a small educational services company with deep roots in natural medicine – and big ambitions to revolutionize the industry. More than 30 years later, the company is pioneering new approaches to nutritional science, breaking barriers in quality standards, and ultimately transforming the healthcare ecosystem. Through a robust product pipeline and a diverse portfolio of more than 300 nutritional products, Designs for Health is leading the charge in the natural and integrative medicine movement to design a well world for all. Whole Beauty Collagen, Collagen + MCT, and Whole Body Collagen are unflavored and unsweetened, making them easy to add to any beverage or shake. They are gluten-free, dairy-free, soy-free, and non-GMO, and available to purchase at . To learn more about Designs for Health and its comprehensive portfolio of products, including its line of oral health products, visit . Please tune in to Designs for Health's new podcast, Conversations for Health, and immerse yourself in the current landscape of Functional Medicine to empower you to design a well world with us. About Designs for Health, Inc. Family-owned Designs for Health, Inc. offers high-quality dietary supplements and functional foods to healthcare professionals and their patients. Guided by its founding philosophy of "Science-First™," the company holds an unwavering commitment to creating research-driven formulations with meaningful quantities of functional ingredients that maximize the potential for successful health outcomes. For over 30 years, Designs for Health has been many healthcare professionals' trusted source for not only product innovation but also leadership in clinical education and practice development solutions. **Awarded by Food Business Review *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Contact: 5WPR 212-999-5585 [email protected] SOURCE Designs for Health

100 Deals associated with Biotin

External Link

KEGG	Wiki	ATC	Drug Bank
D00029	Biotin	A11HA05	DB00121

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	-	-	-
Eczema	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	NDA/BLA	European Union	MedDay Pharmaceuticals SA	-
Adrenoleukodystrophy	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2014
Adrenoleukodystrophy	Phase 3	Germany	MedDay Pharmaceuticals SA	01 Oct 2014
Adrenoleukodystrophy	Phase 3	Spain	MedDay Pharmaceuticals SA	01 Oct 2014
Multiple Sclerosis, Chronic Progressive	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Optic Neuritis	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Optic Neuritis	Phase 3	United Kingdom	MedDay Pharmaceuticals SA	01 Oct 2013
Vision, Low	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Vision, Low	Phase 3	United Kingdom	MedDay Pharmaceuticals SA	01 Oct 2013
Charcot-Marie-Tooth Disease, Type Ia	Phase 2	France	MedDay Pharmaceuticals SA	05 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2023	Not Applicable	-	61	Oral biotin	wyuyoqohks(pkuhmvaqej) = kehusyncff pfvdnwjwua (viqhrqxwab ) View more	Positive	11 Oct 2023
				Pyridoxine	wyuyoqohks(pkuhmvaqej) = ulljwwgnyp pfvdnwjwua (viqhrqxwab ) View more
NCT02936037 (SPI2, Pubmed) Manual	Phase 3	Multiple Sclerosis, Chronic Progressive	642	MD1003	wozgzlcgui(pvcrkeoste) = gmhoqjuzjf bvqyffeaxb (kjotwblolv ) View more	Negative	01 Dec 2020
				Placebo	wozgzlcgui(pvcrkeoste) = dxmufsngld bvqyffeaxb (kjotwblolv ) View more
NCT02936037 (SPI2, CTgov)	Phase 3	Multiple Sclerosis, Chronic Progressive	642	PLACEBO (GROUP 1)	szmslntjcn(uhymbxrecx) = pjasqmsxsj mvaprxbaob (mrutdofmry, cwvylixxpo - byliwzwpqw) View more	-	23 Nov 2020
				MD1003 100mg capsule (GROUP 2)	szmslntjcn(uhymbxrecx) = fyrpuvxqyf mvaprxbaob (mrutdofmry, mblrqprfqa - xvybndyish) View more
NCT02967679 (CTgov)	Phase 2	Charcot-Marie-Tooth Disease, Type Ia \| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating \| Central Nervous System Diseases ... View more	15	MD1003	bddpuzxzex(kjpckpzwxl) = qtvbrbptii yzogpprilq (hqpobebyie, 11.45) View more	-	02 Nov 2020
NCT04223232 (CTgov)	Phase 1	-	6	[14C]-MD1003	icgjnyhupk(apbbpmcjfm) = dizssqyvfb nxhqivhore (twdxcafiji, 16.9) View more	-	02 Nov 2020
ECTRIMS2019	Not Applicable	Multiple Sclerosis	579	MD1003 high dose pharmaceutical-grade biotin	aemrxpxtoq(qlbgxvzkyo) = dwfoposiet btytynlpgz (rzydcibohc )	Positive	10 Sep 2019
				Concomitant immunotherapy	aemrxpxtoq(qlbgxvzkyo) = jzrrqqrcmx btytynlpgz (rzydcibohc )
NCT02220933 (MS-SPI, ECTRIMS2019)	Phase 3	Multiple Sclerosis	133	MD1003	totsjjljew(xjeewbnmci) = The main reasons for treatment withdrawal (M12 to M60) were: perceived lack of efficacy (34 patients), consent withdrawal (23 patients), and discontinuations due to AEs (8 patients) fhisbhhijs (qcmqbrltzh ) View more	Positive	10 Sep 2019
NCT02220933 (MS-SPI, AAN2019)	Phase 3	Multiple Sclerosis, Chronic Progressive	154	MD1003	esobatqsid(osfzbvuajy) = lhsuterjrt evmtrjtmht (uhaaighnqu ) View more	Positive	09 Apr 2019
				Placebo	esobatqsid(osfzbvuajy) = lpkkdbuqhn evmtrjtmht (uhaaighnqu ) View more
NCT02936037 (SPI2, ECTRIMS2018)	Phase 3	Multiple Sclerosis	660	MD1003 300 mg/day	dolntpieeu(mfcfvttitc) = wyouqtfzwx cwpzmhurur (twgpftcxlk )	-	09 Oct 2018
				Placebo	dolntpieeu(mfcfvttitc) = xlyiohkace cwpzmhurur (twgpftcxlk )
NCT02220933 (MS-SPI, ECTRIMS2018)	Phase 3	Multiple Sclerosis	154	MD1003	giejcusapu(dcnjggdjed) = A total of 38% vs 34% of pts in MM and PM groups, respectively, experienced AEs eegexdpfcn (ztuyvhbbbu )	Positive	09 Oct 2018
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Biotin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation